AzTrials
AzTrials

AngiographyNCT03369886

The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI

A study testing Optical Coherence Tomography Angiography (OCTA) in people with Angiography and Glaucoma, Open-Angle, run by Pusan National University Hospital at 1 site in South Korea.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Macular GCIPLT and vessel density will be measured with Spectralis optical coherence tomography and Topcon swept-source OCT respectively. Linear, quadratic and exponential regression models will be used to investigate relationship between GCIPLT and vessel density. Read more about this study

Who is it for?
Ages 19 years and olderHealthy volunteers can take part
Conditions the study is for
Angiography, Glaucoma, Open-Angle
What is being tested?
Optical Coherence Tomography Angiography (OCTA)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
206 participants
Where
1 siteSouth Korea
Study dates
25 Sep 2017to 31 Aug 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • participants were age > 18 years
  • clear cornea and clear ocular media
  • BCVA ≥ 20/40
  • a refractive error within ± 6.0 diopters (D), and astigmatism ± 3.0 D.

Who cannot join

  • History of diabetes, uveitis, secondary glaucoma
  • corneal abnormalities, non-glaucomatous optic neuropathies
  • Previous ocular trauma
  • Previous ocular surgery or laser treatment,
  • Any other eye disease except for glaucoma

Trial locations and contacts

1 site in 1 country.

South Korea1 site, 1 recruiting
  • Pusan National University Hospital

    Busan, 49214

    Jiwoong Lee, M.D., Ph.D, +821020407706, alertlee@naver.com

    Keunheung Park, M.D., +821056540115, climyth@naver.com

    Recruiting

Other trials in South Korea

About this study

Official title: The Relationship Between Macular Optic Coherence Tomography Angiography and Ganglion Cell Layer and Their Combinational Index Using Artificial Neural Network

Macular GCIPLT and vessel density will be measured with Spectralis optical coherence tomography and Topcon swept-source OCT respectively. Linear, quadratic and exponential regression models will be used to investigate relationship between GCIPLT and vessel density. Multilayer neural network will bel used to make single combined parameter and the diagnostic performance will be also compared.

Read the detailed description

This is a prospective, cross-sectional study. All recruited glaucoma patients and healthy subjects will be underwent a complete ophthalmic examination including measurement of the best-corrected visual acuity (BCVA), a slit-lamp examination, gonioscopy, funduscopy, biometry using the IOL Master (Carl Zeiss Meditec, Dublin, CA, USA), and standard automated perimetry (SAP). Central corneal thickness (CCT) will be measured using ultrasonic pachymetry (Pachmate; DGH Technology, Exton, PA, USA). Keratometry will be measured with an Auto Kerato-Refractometer (ARK-510A; NIDEK, Hiroshi, Japan). All of the patients will be also examined using red-free RNFL photographs and optic disc stereoscopic photographs. Two different OCT exam will be performed to measure macular GCIPLT and macular vessel density, spectral domain optic coherence tomography (SD-OCT) and swept source optic coherence tomography angiography (SS-OCTA), respectively.

<Optical Coherence Tomography Angiography Imaging> The macular angiographic images will be obtained using a swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. This methodology is termed as OCTARA (OCT Angiography Ratio Analysis) algorithm where calculations are based on a ratio between the intensity values across points within one scan, and identical points in the repeated scans. OCTARA provides relative sensitivity advantage of the order of 10 ~ 50 times for medium to low blood flow. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).

The investigators developed a custom windows software with Microsoft Visual studio 2012 and C# language with a dot net library. This software calculates the sectoral average vessel density exactly matching to the GCIPL sectors. It requires two image files, superficial vascular layer image and color vessel density map, exported from OCTA instrument. Once after two image files were loaded, fovea is automatically detected but in case software fails, user can manually set foveal location. Then, it calculates mean sectoral vessel density between two ellipsoidal boundaries, outer boundary 4800 x 3000 µm and inner boundary 1200 x 1000 µm (width x height) centered on fovea. This diameter of inner and outer ellipse and angle of sectorization is exactly matched to the GCIPL sectorization. The mean vessel density was calculated from color density map. First, custom software scans all pixel colors within the sectoral boundary. Then, each pixel colors are converted to the vessel density values according to the manufacturer's guide. Finally, it takes average of all vessel density values. This mean vessel density is a unitless value ranged from 0 to 100.

<Spectral-Domain Optical Coherence Tomography Imaging> The Cirrus SD-OCT instrument (Carl Zeiss Meditec, Software version 6.0) will be used to measure macular GCIPLT. After pupil dilation using 0.5% tropicamide and 0.5% phenylephrine, a single macular scan (200 × 200 macular cube scan protocol) of each eye was acquired. The GCA algorithm automatically segmented the GCIPL and RNFL and calculated the thickness of the macular GCIPL and RNFL within a 14.13 mm2 elliptical annulus area centered on the fovea. The inner and outer ellipsoidal boundary is exactly matched to the sectoral vessel density calculated by our custom software. Average, minimum, and six sectoral (superotemporal, superior, superonasal, inferonasal, inferior, and inferotemporal) GCIPLT values were obtained. For quality control, the investigators set the minimum signal strength of all included SD-OCT scans to 6.0.

Being tested
Optical Coherence Tomography Angiography (OCTA)
Keywords
OCTA, Angiography, Artificial neural network
Medical subject headings
Glaucoma, Open-Angle

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Optical Coherence Tomography Angiography (OCTA)Diagnostic test

    The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).

Study groups in NCT03369886
Study groupRoleWhat they receive
Early glaucoma groupOtherPatients whose visual field mean deviation is > -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
Receives: Diagnostic Test: Optical Coherence Tomography Angiography (OCTA)
Advanced glaucoma groupOtherPatients whose visual field mean deviation is < -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
Receives: Diagnostic Test: Optical Coherence Tomography Angiography (OCTA)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Vessel density

    Macular vessel density measured by optical coherence tomography angiography

    Measured: 20 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2017
  2. Study start25 Sep 2017
  3. Primary completion31 Aug 2018 (estimated)
  4. Study completion31 Aug 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
3 subject groups: 1. Normal control: Subjects who has normal fundus, normal visual field and normal intraocular pressure. 2. Early glaucoma: : Patients who shows glaucomatous visual field abnormality but visual field mean deviation is \> -6 dB 3. Advanced glaucoma : Patients who shows glaucomatous visual field abnormality but visual field mean deviation is \< -6 dB
Masking
None (open label)
Enrolment
206 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03369886
Sponsor's protocol ID
1708-037-058
Status last verified
Dec 2017
First submitted
6 Dec 2017
Last updated
29 Dec 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Unpersonalized measurement data and ophthalmic examination data can be shared with other researchers.

Publications

  • Leveque PM, Zeboulon P, Brasnu E, Baudouin C, Labbe A. Optic Disc Vascularization in Glaucoma: Value of Spectral-Domain Optical Coherence Tomography Angiography. J Ophthalmol. 2016;2016:6956717. doi: 10.1155/2016/6956717. Epub 2016 Feb 22.

    PubMed 26998352
  • Rao HL, Pradhan ZS, Weinreb RN, Riyazuddin M, Dasari S, Venugopal JP, Puttaiah NK, Rao DA, Devi S, Mansouri K, Webers CA. A comparison of the diagnostic ability of vessel density and structural measurements of optical coherence tomography in primary open angle glaucoma. PLoS One. 2017 Mar 13;12(3):e0173930. doi: 10.1371/journal.pone.0173930. eCollection 2017.

    PubMed 28288185
  • Suh MH, Zangwill LM, Manalastas PI, Belghith A, Yarmohammadi A, Medeiros FA, Diniz-Filho A, Saunders LJ, Weinreb RN. Deep Retinal Layer Microvasculature Dropout Detected by the Optical Coherence Tomography Angiography in Glaucoma. Ophthalmology. 2016 Dec;123(12):2509-2518. doi: 10.1016/j.ophtha.2016.09.002. Epub 2016 Oct 18.

    PubMed 27769587

Questions about this trial

What is this clinical trial studying?

A study testing Optical Coherence Tomography Angiography (OCTA) in people with Angiography and Glaucoma, Open-Angle, run by Pusan National University Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Vessel density (time frame: 20 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03369886, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in